

File reference	W18FOI155
Key words	Haemophilia Treatments
Date of release	26/07/2018
Attachments	No

Freedom of Information Act Disclosure log - Reply Extract

You asked

In the last 6 months [latest 6 months of data you have available], how many patients with Haemophilia A have been treated with:

	UPHT response
Advate	Refused in compliance with section 40.- (2)(a) and (b) by virtue of section 40.- (3)(a)(i) or not held and section 14.(2). Please refer to the legal notes
Afstyla	As above
Elocta	As above
Emicizumab	As above
Factor Eight Inhibitor Bypass Activity (FEIBA)	As above
NovoEight	As above
Kogenate	As above
Helixate	As above
NovoSeven RT	As above
Nuwiq	As above
Refacto AF	As above
Other [please state]	As above

If possible, could you also supply the above data, but split by severity as follows:

	Mild (factor level >5%)	Moderate (factor level 1-5%)	Severe (factor level <1%)
Advate	Refused in compliance with section 40.- (2)(a) and (b) by virtue of section 40.- (3)(a)(i) or not held	Refused in compliance with section 40.- (2)(a) and (b) by virtue of section 40.- (3)(a)(i) or not held	Refused in compliance with section 40.- (2)(a) and (b) by virtue of section 40.- (3)(a)(i) or not held
Afstyla	Not	Not	Not

	applicable	applicable	applicable
Elocta	Not applicable	Not applicable	Not applicable
Emicizumab	Not applicable	Not applicable	Not applicable
Factor Eight Inhibitor Bypass Activity (FEIBA)	Not applicable	Not applicable	Not applicable
NovoEight	Not applicable	Not applicable	Not applicable
Kogenate	Refused in compliance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i) or not held	Refused in compliance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i) or not held	Refused in compliance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i) or not held
Helixate	Not applicable	Not applicable	Not applicable
NovoSeven RT	Not applicable	Not applicable	Not applicable
Nuwiq	Not applicable	Not applicable	Not applicable
Refacto AF	Refused in compliance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i) or not held	Refused in compliance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i) or not held	Refused in compliance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i) or not held
Other [please state]	Not applicable	Not applicable	Not applicable

In the last 6 months [latest 6 months of data you have available], how many patients with Haemophilia B have been treated with:

Alprolix	Refused in compliance with section 14.(2). Please refer to the legal notes
Benefix	Refused in compliance with section 14.(2). Please refer to the legal notes
Idelvion	Refused in compliance with section 14.(2). Please refer to the legal notes
Rixubis	Refused in compliance with section 14.(2). Please refer to the legal notes
Other [please state]	Refused in compliance with section 14.(2).

Please refer to the legal notes

As with Haemophilia A, if possible please could you split the information by severity?

	Mild (factor level >5%)	Moderate (factor level 1%-5%)	Severe (factor level <1%)
Alprolix	Not applicable	Not applicable	Not applicable
Benefix	Not applicable	Not applicable	Not applicable
Idelvion	Not applicable	Not applicable	Not applicable
Rixubis	Not applicable	Not applicable	Not applicable
Other [please state]	Not applicable	Not applicable	Not applicable

If you use PK tools, please can you supply the number of patients in the last 6 months using the following:

PK Tool	Volume
WAPPS	The Trust does not record the number of patients using such devices.
myPKFIT	As above
Doseme	As above
Optims	As above

Our legal notes

The Trust made public this reply on the 12/03/2018 to another applicant. The evidence would suggest its style reflects the same body corporate, despite gmail addresses that do not identify the company making each request.

This is reply we provided on 27/02/2018 to a request received 12/02/2018

You asked

In the last 6 months [latest 6 months of data you have available], how many patients with Haemophilia A have been treated with:

Advate = Five or fewer

Afstyla = 0

Elocta = 0

Emicizumab = 0

Factor Eight Inhibitor Bypass Activity (FEIBA) = 0

Kogenate = Five or fewer

Helixate = 0

NovoSeven RT = 0

Nuwiq = 0

Refacto AF = Five or fewer

Other [please state] = 0

In the last 6 months [latest 6 months of data you have available], how many patients with Haemophilia B have been treated with:

Alprolix = 0

Benefix = 0

Idelvion = 0

Rixubis = 0

Other [please state] = 0

N:B - Does not include patients who are on home delivery / laboratory does hold this information.

Legal notes

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles and the general right to object to processing. This is in accordance with section 40.-(2)(a) and (b) by virtue of the first and second condition.

Attachments included: No